Lung cancer is the leading cause of cancer deaths worldwide, with a 5-year survival rate of just 18%. Surgery remains crucial for treating early-stage (IA/B) and select locally advanced (II-IIIA/B) non-small cell lung cancer (NSCLC). However, advancements in systemic therapies and surgical techniques have shifted the focus to "resectability." To address this, the Society of Thoracic Surgeons convened a multidisciplinary expert panel of thoracic surgeons and oncologists specializing in lung cancer management to develop guidance on managing locally advanced NSCLC.
The panel reviewed the latest clinical studies and developed a consensus on surgical appropriateness and the use of neoadjuvant and adjuvant therapies in managing locally advanced NSCLC. This article outlines the key recommendations from their expert consensus. Key recommendations A multidisciplinary team (MDT) comprising…
